• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

IL-34: New, possible target to tackle drug-resistant cancer cells

Bioengineer by Bioengineer
October 3, 2016
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A team of researchers has discovered that chemoresistant lung cancer cells suppress immune functions and strengthen resistance to chemotherapy by producing interleukin-34 (IL-34) — a type of cytokine.

Chemoresistant cancer cells secrete IL-34, which induces production of immunosuppressive macrophages and enhances chemoresistance of the cancer cells. Credit: Image courtesy of Hokkaido University
Chemoresistant cancer cells secrete IL-34, which induces production of immunosuppressive macrophages and enhances chemoresistance of the cancer cells.
Credit: Image courtesy of Hokkaido University

Chemotherapy is one of the most important treatments for many cancer patients. In recent years, chemotherapies that target the immune system have been developed, resulting in remarkable advances in cancer treatments. However, the ability of tumor cells to escape immune destruction and acquire resistance to chemotherapy remain major obstacles to effective cancer therapy.

It is known that immunosuppressive macrophages accumulate at tumor sites where the tumor cells have become resistant to chemotherapy. Assistant Professor Muhammad Baghdadi, Lecturer Haruka Wada and Professor Ken-ichiro Seino of the Division of Immunobiology at Hokkaido University’s Institute for Genetic Medicine, conducted research with collaborators based on a theory that chemoresistant tumor cells produce an unidentified substance that increases tumor-associated macrophages, thus enhancing their resistance to chemotherapy.

In the latest research, the team cultivated chemosensitive A549-DS, made from A549 lung cancer cells, together with the chemotherapeutic drug doxorubicin, to create doxorubicin-resistant A549-DR. The researchers examined the two cells, finding a large amount of IL-34 was produced in the A549-DR, but not in the A549-DS. They also found that the IL-34 produced by A549-DR contributed to the production of immunosuppressive macrophages. Furthermore, their experiment showed that IL-34 enhanced the chemoresistance of A549-DR.

In experiments using mice, researchers found that A549-DR was resistant to the chemotherapeutic drug when transplanted in mice, while A549-DR with depleted IL-34 became sensitive to the same drug, suggesting that IL-34 enhanced chemoresistance in the animal body.

Furthermore, researchers discovered high levels of IL-34 in tumors removed from several lung cancer patients. They also examined the prognoses of post-operative patients — studying those with, and those without IL-34 in their tumors, finding that the former’s prognoses were poorer than the latter’s.

“Currently, there are only a few options to treat chemoresistant tumors.,” Professor Seino said. “This latest finding could make it possible to develop a new therapy, which targets IL-34, to treat chemoresistant cancer cells.”

Web Source:

Materials provided by Hokkaido University.

Journal Reference:

Baghdadi M. et. al. Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Research, October 2016 DOI: 10.1158/0008-5472

The post IL-34: New, possible target to tackle drug-resistant cancer cells appeared first on Scienmag.

Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Valencene Guards Against Benzo(a)pyrene Lung Cancer

August 5, 2025
blank

Impact of State-Level Insurance Expansion on Racial Disparities in Breast Density-Based Screening Eligibility

August 5, 2025

Comparing Pre-Surgery Therapies for Esophageal Cancer

August 5, 2025

TIGIT: Emerging Immune Checkpoint Target in Breast Cancer

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    72 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Stability and Refolding of Zika Virus EDIII Protein

Assessing Demirjian Method Reliability Among Forensic Experts

Malaria Rapid Test Accuracy in Young Burkina Faso Children

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.